Michelle McMurry-Heath
About Michelle McMurry-Heath
Michelle McMurry-Heath, MD, PhD (age 55) is an independent director at Revvity (RVTY) since 2022. She is a physician and molecular immunologist, founder and CEO of BioTechquity Clinical (since 2024), and formerly served as CEO of the Biotechnology Innovation Organization (2020–2022) and senior leadership roles at Johnson & Johnson (2014–2020). She holds a BA in biochemistry from Harvard and an MD/PhD from Duke’s Medical Scientist Training Program, where she was the first African American graduate .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Biotechnology Innovation Organization (BIO) | President & CEO | 2020–2022 | Led largest biotech advocacy group; industry engagement and policy influence |
| Johnson & Johnson | Global Head of Evidence Generation (Medical Devices); VP Global External Innovation; Global Leader for Regulatory Sciences | 2014–2020 | External innovation, regulatory strategy, evidence generation across devices |
| U.S. FDA (CDRH) | Associate Science Director | Not disclosed | Science policy leadership; regulatory science contributions |
| Aspen Institute | Founding Director, Health, Biomedical Science & Society Policy Program | Not disclosed | Established program bridging science and policy |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| BioTechquity Clinical | Founder & CEO | 2024–Present | CRO focused on diverse clinical trial enrollment |
| Bioventus Inc. (public) | Director | Current | Public company board service; committee roles not disclosed in RVTY proxy |
Board Governance
- Committee assignment: Compensation & Benefits (member) .
- Independence: Affirmed independent under NYSE standards; compensation committee members are independent .
- Attendance/engagement: Board met 6 times in FY2024; each director attended ≥75% of combined board and committee meetings; all directors attended the virtual annual meeting .
- Board structure: 10 directors; 9 independent; Independent Non‑Executive Chair; majority voting for director elections in uncontested meetings; executive sessions of independent directors at each regular meeting .
- Compensation committee operations: 5 meetings in FY2024; retains independent consultant (Pearl Meyer); no compensation committee interlocks; authority to retain/terminate advisors .
- Trading policy: Prohibits directors/officers/employees from short sales, options/derivatives, and hedging; officers may not pledge company stock .
- Related party transactions: Oversight by Nominating & Corporate Governance; policy requires review/approval; no director-specific related party transactions disclosed .
Fixed Compensation
| Component | Amount | Detail | Grant/Payment Date |
|---|---|---|---|
| Annual cash retainer | $90,000 | Standard non-employee director retainer; paid quarterly (May/Aug/Nov/Feb) | FY2024 board year |
| Committee chair/member fees | $0 | Not a chair; no additional cash fee disclosed for members | FY2024 |
| Stock award (shares) | $124,967 | 1,218 common shares; not subject to vesting/restrictions | Granted May 1, 2024 |
| RSU grant | $99,967 | 977 RSUs; 1:1 share on vest | Granted May 1, 2024 |
| Total 2024 director compensation | $314,933 | Cash + equity fair values | FY2024 |
| 2024 Director Equity Grant Detail | Units | Fair Value | Vesting |
|---|---|---|---|
| Common stock grant | 1,218 | $124,967 | N/A (fully unrestricted at grant) |
| RSUs | 977 | $99,967 | 100% vests at next annual meeting date (April 22, 2025) or earlier upon death, disability, qualifying retirement, or termination within 12 months post-change in control |
Notes:
- Unvested RSUs held at FY2024 year-end: 977 .
- Equity retainer increased by $25,000 effective April 23, 2024 for directors (to $225,000 total equity retainer); no changes for 2025 .
Performance Compensation
| Item | Status | Notes |
|---|---|---|
| Director performance-based incentives | None | RVTY director equity is time-based (common shares + RSUs), no performance metrics for directors; RSUs vest on annual meeting schedule |
Other Directorships & Interlocks
| Company | Industry Relation to RVTY | Role/Committee | Potential Conflict Assessment |
|---|---|---|---|
| Bioventus Inc. | Orthobiologics; not a direct competitor to life science tools/diagnostics core | Director (committee roles not disclosed in RVTY proxy) | No interlocks or related-party transactions disclosed; low direct conflict based on industry scope |
Expertise & Qualifications
- Medical doctor and molecular immunologist; 12 years bench research experience .
- Executive experience in regulatory science, external innovation, evidence generation (J&J) .
- National policy/regulatory leadership (FDA CDRH, NSF analysis) .
- Advocacy leadership as BIO CEO; focus on broadening access to scientific progress and bioequality .
- Public company board experience (Bioventus) .
Equity Ownership
| Metric | Amount | Notes |
|---|---|---|
| Shares beneficially owned (Feb 14, 2025) | 3,021 | Direct holdings; no stock-based holdings/derivative positions reported |
| Acquirable within 60 days | 0 | No exercisable options/RSUs within 60 days |
| Unvested RSUs (Dec 29, 2024) | 977 | Scheduled to vest at 2025 annual meeting date (subject to conditions) |
| Options held | 0 | None of non‑employee directors held stock options at FY2024 year-end |
| Ownership guidelines | 5x cash retainer ($450,000) within 5 years; all directors compliant as of Feb 14, 2025 | Director stock ownership guideline policy and compliance |
| Shares outstanding (record date) | 120,147,286 | Record date for 2025 annual meeting |
| Ownership as % of shares outstanding | ~0.0025% | Computed from 3,021 / 120,147,286; inputs cited above |
Governance Assessment
- Board effectiveness: Active engagement via Compensation & Benefits committee (5 meetings in 2024) and independent governance architecture; presence of independent consultant (Pearl Meyer) supports rigorous pay oversight .
- Independence & conflicts: Independent under NYSE standards; no related-party transactions disclosed; external directorship at Bioventus presents limited conflict given industry differences and no transactions noted with RVTY .
- Attendance & engagement: Met ≥75% attendance thresholds and participated in fully virtual annual meeting; signals commitment to board duties .
- Incentive alignment: Director pay mix emphasizes equity (unrestricted shares + time-based RSUs), reinforcing alignment; directors subject to stock ownership guidelines (5x retainer) with company reporting full compliance as of Feb 14, 2025 .
- Risk indicators: Trading policy prohibitions on short sales, derivatives, and hedging for directors; officers prohibited from pledging; combined with stringent related-party policy reduces governance risk .
- Shareholder signals: 2024 Say-on-Pay support at 95.7% indicates broad investor confidence in compensation oversight, indirectly reflecting board credibility .
RED FLAGS: None disclosed regarding attendance shortfalls, related-party transactions, hedging/pledging, or compensation committee interlocks for this director .